(Q37399063)

20 August 2017

1 reference

title

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review (English)

1 reference

20 August 2017

0 references

1 reference

Andrea Cassinotti

1

1 reference

PubMed ID

19235918

20 August 2017

Simon Travis

series ordinal

2

1 reference

20 August 2017

1 August 2009

1 reference

Inflammatory Bowel Diseases

20 August 2017

1 reference

20 August 2017

15

1 reference

20 August 2017

8

1 reference

20 August 2017

1264-1275

1 reference

European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis

20 August 2017

1 reference

Review article: Infliximab therapy for inflammatory bowel disease--seven years on

21 January 2018

1 reference

Optimizing anti-TNF treatment in inflammatory bowel disease

21 January 2018

1 reference

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease

21 January 2018

1 reference

Immunogenicity of therapeutic proteins: clinical implications and future prospects

21 January 2018

1 reference

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

21 January 2018

1 reference

Physiological and pathological aspects of circulating immune complexes

21 January 2018

1 reference

Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis

21 January 2018

1 reference

Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys.

21 January 2018

1 reference

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

21 January 2018

1 reference

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial

21 January 2018

1 reference

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease

21 January 2018

1 reference

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

21 January 2018

1 reference

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

21 January 2018

1 reference

Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IBD.20899

1 reference

20 August 2017

1 reference

PubMed ID

19235918